ArticlePloS one2020

Implantable cardioverter defibrillator therapy is cost effective for primary prevention patients in Taiwan: An analysis from the Improve SCA trial.

Reece Holbrook et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.